Trial of Venovenous ECMO to De-Sedate, Extubate and Mobilise in Hypoxic Respiratory Failure (NCT05562505) | Clinical Trial Compass
RecruitingNot Applicable
Trial of Venovenous ECMO to De-Sedate, Extubate and Mobilise in Hypoxic Respiratory Failure
Australia140 participantsStarted 2022-11-28
Plain-language summary
To determine whether a strategy of adding venovenous ECMO to mechanical ventilation, as compared to mechanical ventilation alone, increases the number of intensive care free days at day 60, in patients with moderate to severe acute hypoxic respiratory failure.
Who can participate
Age range18 Years ā 65 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
ā. Patients ā„18 to 65 years old
ā. Acute hypoxemic respiratory failure characterised by new or worsening respiratory symptoms developing within 2 weeks prior to the onset of need for oxygen or respiratory support
ā. Mechanical ventilation of \<7 days
ā. Moderate to severe respiratory failure, as demonstrated by two P:F ratios \<150mmHg at least 6 hours apart. Arterial Blood Gases (ABG) with P:F ratio \> 150mmHg are permitted between the two trial inclusion ABGs.
ā. Trial of proning (unless contraindicated)
Exclusion criteria
ā. The patient will be extubated today or tomorrow (i.e. will not remain intubated and ventilated the day after tomorrow)
ā. Cardiogenic cause of respiratory failure
ā. Chronic hypercapnic respiratory failure defined as PaCO2 \> 60 mmHg in the outpatient setting
ā. Home mechanical ventilation (non-invasive ventilation or via tracheotomy) except for CPAP/BIPAP used solely for sleep disordered breathing
ā. Confirmed diffuse alveolar haemorrhage from vasculitis
ā. Neurologic conditions, i.e. undergoing treatment for intracranial hypertension
ā. Currently receiving any form of ECMO (e.g., venovenous, venoarterial, or hybrid configuration)
What they're measuring
1
Intensive Care Unit Free days to Day 60
Timeframe: 60 Days
Trial details
NCT IDNCT05562505
SponsorAustralian and New Zealand Intensive Care Research Centre